131 related articles for article (PubMed ID: 29994072)
1. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
Moon S; Balch C; Park S; Lee J; Sung J; Nam S
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
[TBL] [Abstract][Full Text] [Related]
2. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T; Shibata T; Okamoto Y; Yamazaki J; Kawamura T; Horiguchi N; Okubo M; Nakano N; Ishizuka T; Nagasaka M; Nakagawa Y; Ohmiya N
Oncotarget; 2016 Jul; 7(27):42252-60. PubMed ID: 27323394
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
4. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
6. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.
Seagle BL; Eng KH; Dandapani M; Yeh JY; Odunsi K; Shahabi S
Oncotarget; 2015 Jul; 6(21):18641-52. PubMed ID: 26215675
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations.
Park S; Lee J; Kim YH; Park J; Shin JW; Nam S
Sci Rep; 2016 Oct; 6():34822. PubMed ID: 27708434
[TBL] [Abstract][Full Text] [Related]
9. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma.
Lapke N; Lu YJ; Liao CT; Lee LY; Lin CY; Wang HM; Ng SH; Chen SJ; Yen TC
Oncotarget; 2016 Jul; 7(28):44194-44210. PubMed ID: 27283772
[TBL] [Abstract][Full Text] [Related]
11. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.
Fischer NW; Prodeus A; Gariépy J
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089713
[TBL] [Abstract][Full Text] [Related]
12. P53 deregulation in Epstein-Barr virus-associated gastric cancer.
Ribeiro J; Malta M; Galaghar A; Silva F; Afonso LP; Medeiros R; Sousa H
Cancer Lett; 2017 Sep; 404():37-43. PubMed ID: 28729047
[TBL] [Abstract][Full Text] [Related]
13. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
14. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.
Kohno Y; Yamamoto H; Hirahashi M; Kumagae Y; Nakamura M; Oki E; Oda Y
Hum Pathol; 2016 Jun; 52():145-52. PubMed ID: 26980051
[TBL] [Abstract][Full Text] [Related]
15. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
16. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
17. Identification of critical pathways and hub genes in
Sun J; Zhang K; Cai Z; Li K; Zhao C; Fan C; Wang J
Biomark Med; 2019 Jul; 13(10):831-840. PubMed ID: 31116024
[No Abstract] [Full Text] [Related]
18. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB; Kreisberg JF; Carter H
PLoS One; 2016; 11(4):e0152929. PubMed ID: 27043210
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
